Inhaltsbereich

 

 

Forschungsgebiet:

 

Untersuchung von Signalwegen, die Wachstum, Überleben und Apoptose von Krebszellen regulieren

 
Projekte:

Rezeptortyrosinkinasen als Angriffspunkte für  Krebstherapien

Signalwege, die von Rezeptortyrosinkinasen (RTKs) der FGF-Rezeptor Familie (fibroblast growth factor) und der EGF-Rezeptor Familie (epidermal growth factor) reguliert werden, sind in vielen menschlichen Krebsarten überaktiviert. Unsere Forschung dient dem Ziel (1.) zu verstehen, wie diese Signale das Wachstum und Überleben von Krebszellen kontrollieren (2.) dieses Wissen für die Entwicklung neuer Krebstherapien nutzbar zu machen (3.) die Mechanismen zu charakterisieren, die über das Ansprechen bzw. die Resistenz gegenüber Therapien mit Inhibitoren dieser RTKs bestimmen.

 

 

 

Lehre:


Vorlesung: Rezeptortyrosinkinasen in der Krebsentstehung und Therapie (Winter)
Vorlesung: Methods of Gene Transfer into Human Cells and their Application for Research and Therapy (Sommer)
Vorlesungsteil im Basic Seminar: Malignant Diseases 1 (Winter)
Vorlesungsteil im: Toxicology Course Vienna
Seminar Tumor 1 und 2 im Block 8: Krankheit, Krankheitsursachen und Krankheitsbilder (Winter)
Journal Club (zusammen mit Walter Berger): Molecular Mechanisms of Cancer Therapeutics
Seminar mit Praktikum: SSM-3 Projektstudie

Termine und LV Nummern

Download von Vorlesungsunterlagen (passwortgeschützt)

Geldgeber:


Initiative Krebsforschung der Medizinischen Universität Wien
Herzfeldersche Familienstiftung
Jubiläumsfonds der Österreichischen Nationalbank
Hochschuljubiläumsstiftung
Fonds der Stadt Wien für innovative interdisziplinäre Krebsforschung

Publikationen:


Siehe auch Einträge in der Pubmed Datenbank und Profil auf Researcher ID

 

2012

 

Lackner, A., Kreidl E., Peter-Vorosmarty B., Spiegl-Kreinecker S., Berger W., Grusch M. (2012). Stable protein expression in mammalian cells using baculoviruses. Methods Mol Biol. 801, 75-92.

 

2011

 

Brunner-Kubath, C., Shabbir W., Saferding V., Wagner R., Singer C. F., Valent P., Berger W., Marian B., Zielinski C. C., Grusch M., Grunt T. W. (2011). The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. Breast Cancer Res Treat. 129, 387-400.

 

Elbling, L., Herbacek I., Weiss R. M., Gerner C., Heffeter P., Jantschitsch C., Trautinger F., Grusch M., Pangratz H., Berger W. (2011). EGCG-meditated cyto- and genotoxicity in HaCat keratinocytes is impaired by cell-mediated clearance of auto-oxidation-derived H2O2: an algorithm for experimental setting correction. Toxicol Lett. 205, 173-182.

 

Frost, K., Seir K., Lackner A., Grusch M., Grasl-Kraupp B., Schulte-Hermann R., Rodgarkia-Dara C. (2011). Inhibin/activin expression in human and rodent liver: subunits alpha and betaB as new players in human hepatocellular carcinoma? Br J Cancer. 104, 1303-1312.

 

Gauglhofer, C., Sagmeister S., Schrottmaier W., Fischer C., Rodgarkia-Dara C., Mohr T., Stattner S., Bichler C., Kandioler D., Wrba F., Schulte-Hermann R., Holzmann K., Grusch M., Marian B., Berger W., Grasl-Kraupp B. (2011). Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis. Hepatology. 53, 854-864.

 

Heinzle, C., Sutterluty H., Grusch M., Grasl-Kraupp B., Berger W., Marian B. (2011). Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy. Expert Opin Ther Targets. 15, 829-846.

 

Hoda, M. A., Mohamed A., Ghanim B., Filipits M., Hegedus B., Tamura M., Berta J., Kubista B., Dome B., Grusch M., Setinek U., Micksche M., Klepetko W., Berger W. (2011). Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy. J Thorac Oncol. 6, 852-863.

 

Metzner, T., Bedeir A., Held G., Peter-Vorosmarty B., Ghassemi S., Heinzle C., Spiegl-Kreinecker S., Marian B., Holzmann K., Grasl-Kraupp B., Pirker C., Micksche M., Berger W., Heffeter P., Grusch M. (2011). Fibroblast Growth Factor Receptors as Therapeutic Targets in Human Melanoma: Synergism with BRAF Inhibition. J Invest Dermatol. 131, 2087-2095.

 

Saiko, P., Graser G., Giessrigl B., Lackner A., Grusch M., Krupitza G., Basu A., Sinha B. N., Jayaprakash V., Jaeger W., Fritzer-Szekeres M., Szekeres T. (2011). A novel N-hydroxy-N'-aminoguanidine derivative inhibits ribonucleotide reductase activity: Effects in human HL-60 promyelocytic leukemia cells and synergism with arabinofuranosylcytosine (Ara-C). Biochem Pharmacol. 81, 50-59.

 

Vonach, C., Viola K., Giessrigl B., Huttary N., Raab I., Kalt R., Krieger S., Vo T. P., Madlener S., Bauer S., Marian B., Hammerle M., Kretschy N., Teichmann M., Hantusch B., Stary S., Unger C., Seelinger M., Eger A., Mader R., Jager W., Schmidt W., Grusch M., Dolznig H., Mikulits W., Krupitza G. (2011). NF-kappaB mediates the 12(S)-HETE-induced endothelial to mesenchymal transition of lymphendothelial cells during the intravasation of breast carcinoma cells. Br J Cancer. 105, 263-271.

 

2010

 

Elbling, L., Herbacek I., Weiss R. M., Jantschitsch C., Micksche M., Gerner C., Pangratz H., Grusch M., Knasmuller S., Berger W. (2010). Hydrogen peroxide mediates EGCG-induced antioxidant protection in human keratinocytes. Free Radic Biol Med. 49, 1444-1452.

 

Gerner, C., Haudek-Prinz V. J., Lackner A., Losert A., Peter-Vorosmarty B., Lorenz O., Grusch M. (2010). Indications for cell stress in response to adenoviral and baculoviral gene transfer observed by proteome profiling of human cancer cells. Electrophoresis. 31, 1822-1832.

 

Grusch, M., Berger W. (2010). Fibroblast Growth Factor Receptors (FGFR) as Possible therapeutic targets in human non-small cell lung cancer. MEMO. 3, 23-26.

 

Grusch, M., Petz M., Metzner T., Ozturk D., Schneller D., Mikulits W. (2010). The Crosstalk of RAS with the TGF-beta Family during Carcinoma Progression and its Implications for Targeted Cancer Therapy. Curr Cancer Drug Targets. 10, 849-857.

 

Khan, M., Giessrigl B., Vonach C., Madlener S., Prinz S., Herbaceck I., Holzl C., Bauer S., Viola K., Mikulits W., Quereshi R. A., Knasmuller S., Grusch M., Kopp B., Krupitza G. (2010). Berberine and a Berberis lycium extract inactivate Cdc25A and induce alpha-tubulin acetylation that correlate with HL-60 cell cycle inhibition and apoptosis. Mutat Res. 683, 123-130.

 

Madlener, S., Saiko P., Vonach C., Viola K., Huttary N., Stark N., Popescu R., Gridling M., Vo N. T., Herbacek I., Davidovits A., Giessrigl B., Venkateswarlu S., Geleff S., Jager W., Grusch M., Kerjaschki D., Mikulits W., Golakoti T., Fritzer-Szekeres M., Szekeres T., Krupitza G. (2010). Multifactorial anticancer effects of digalloyl-resveratrol encompass apoptosis, cell-cycle arrest, and inhibition of lymphendothelial gap formation in vitro. Br J Cancer. 102, 1361-1370.

 

Mayer, C. E., Haigl B., Jantscher F., Siegwart G., Grusch M., Berger W., Sutterluty H. (2010). Bimodal expression of Sprouty2 during the cell cycle is mediated by phase-specific Ras/MAPK and c-Cbl activities. Cell Mol Life Sci. 67, 3299-3311.

 

Pirker, C., Lotsch D., Spiegl-Kreinecker S., Jantscher F., Sutterluty H., Micksche M., Grusch M., Berger W. (2010). Response of experimental malignant melanoma models to the pan-Aurora kinase inhibitor VE-465. Exp Dermatol. 19, 1040-1047.

 

Slany, A., Haudek V. J., Zwickl H., Gundacker N. C., Grusch M., Weiss T. S., Seir K., Rodgarkia-Dara C., Hellerbrand C., Gerner C. (2010). Cell characterization by proteome profiling applied to primary hepatocytes and hepatocyte cell lines Hep-G2 and Hep-3B. J Proteome Res. 9, 6-21.

 

Sonvilla, G., Allerstorfer S., Heinzle C., Stattner S., Karner J., Klimpfinger M., Wrba F., Fischer H., Gauglhofer C., Spiegl-Kreinecker S., Grasl-Kraupp B., Holzmann K., Grusch M., Berger W., Marian B. (2010). Fibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration. Br J Cancer. 102, 1145-1156.

 

Vo, N. T., Madlener S., Bago-Horvath Z., Herbacek I., Stark N., Gridling M., Probst P., Giessrigl B., Bauer S., Vonach C., Saiko P., Grusch M., Szekeres T., Fritzer-Szekeres M., Jager W., Krupitza G., Soleiman A. (2010). Pro- and anticarcinogenic mechanisms of piceatannol are activated dose dependently in MCF-7 breast cancer cells. Carcinogenesis. 31, 2074-2081.

 

 

2009

 

Berger, W., Steiner E., Grusch M., Elbling L., Micksche M. (2009). Vaults and the major vault protein: novel roles in signal pathway regulation and immunity. Cell Mol Life Sci.  66, 43-61.

 

Bernhaus, A., Fritzer-Szekeres M., Grusch M., Saiko P., Krupitza G., Venkateswarlu S., Trimurtulu G., Jaeger W., Szekeres T. (2009). Digalloylresveratrol, a new phenolic acid derivative induces apoptosis and cell cycle arrest in human HT-29 colon cancer cells. Cancer Lett.  274, 299-304.

 

Bernhaus, A., Ozsvar-Kozma M., Saiko P., Jaschke M., Lackner A., Grusch M., Horvath Z., Madlener S., Krupitza G., Handler N., Erker T., Jaeger W., Fritzer-Szekeres M., Szekeres T. (2009). Antitumor effects of KITC, a new resveratrol derivative, in AsPC-1 and BxPC-3 human pancreatic carcinoma cells. Invest New Drugs. 27, 393-401.

 

Gridling, M., Stark N., Madlener S., Lackner A., Popescu R., Benedek B., Diaz R., Tut F. M., Nha Vo T. P., Huber D., Gollinger M., Saiko P., Ozmen A., Mosgoeller W., De Martin R., Eytner R., Wagner K. H., Grusch M., Fritzer-Szekeres M., Szekeres T., Kopp B., Frisch R., Krupitza G. (2009). In vitro anti-cancer activity of two ethno-pharmacological healing plants from Guatemala Pluchea odorata and Phlebodium decumanum. Int J Oncol.  34, 1117-28.

 

Grunt, T. W., Wagner R., Grusch M., Berger W., Singer C. F., Marian B., Zielinski C. C., Lupu R. (2009). Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. Biochem Biophys Res Commun.  385, 454-9.

 

Grusch, M., Losert A., Lackner A., Deli A., Herbacek I., Holzmann K. (2009). Microscopic analysis of adenoviral decontamination using GFP adenovirus with comparable sensitivity to flow cytometry. Methods Mol Biol.  515, 125-35.

 

Huber, W. W., Grusch M. (2009) Measurement of Enzymes of Xenobiotic Metabolism in Chemoprevention Research. In Knasmüller, S., DeMarini, D.M., Johnson, I. and Gerhäuser, C. (eds.), Chemoprevention of Cancer and DNA Damage by Dietary Factors. Wiley-Blackwell, Weinheim, pp. 245-261.

 

Kreidl, E., Öztürk D., Metzner T., Berger W., Grusch M. (2009). Activins and Follistatins: Emerging Roles in Liver Physiology and Cancer. World Journal of Hepatology. 1, 17-27.

 

Macheiner, D., Gauglhofer C., Rodgarkia-Dara C., Grusch M., Brachner A., Bichler C., Kandioler D., Sutterluty H., Mikulits W., Schulte-Hermann R., Grasl-Kraupp B. (2009). NORE1B is a putative tumor suppressor in hepatocarcinogenesis and may act via RASSF1A. Cancer Res.  69, 235-42.

 

 

Madlener, S., Rosner M., Krieger S., Giessrigl B., Gridling M., Vo T. P., Leisser C., Lackner A., Raab I., Grusch M., Hengstschlager M., Dolznig H., Krupitza G. (2009). Short 42 degrees C heat shock induces phosphorylation and degradation of Cdc25A which depends on p38MAPK, Chk2 and 14.3.3. Hum Mol Genet.  18, 1990-2000.

 

Madlener, S., Svacinova J., Kitner M., Kopecky J., Eytner R., Lackner A., Vo T. P., Frisch R., Grusch M., De Martin R., Dolezal K., Strnad M., Krupitza G. (2009). In vitro anti-inflammatory and anticancer activities of extracts of Acalypha alopecuroidea (Euphorbiaceae). Int J Oncol.  35, 881-91.

 

Saiko, P., Ozsvar-Kozma M., Graser G., Lackner A., Grusch M., Madlener S., Krupitza G., Jaeger W., Hidvegi M., Agarwal R. P., Fritzer-Szekeres M., Szekeres T. (2009). Avemar, a nontoxic fermented wheat germ extract, attenuates the growth of sensitive and 5-FdUrd/Ara-C cross-resistant H9 human lymphoma cells through induction of apoptosis. Oncol Rep.  21, 787-91.

 

Stark, N., Gridling M., Madlener S., Bauer S., Lackner A., Popescu R., Diaz R., Tut F. M., Vo T. P., Vonach C., Giessrigl B., Saiko P., Grusch M., Fritzer-Szekeres M., Szekeres T., Kopp B., Frisch R., Krupitza G. (2009). A polar extract of the Maya healing plant Anthurium schlechtendalii (Aracea) exhibits strong in vitro anticancer activity. Int J Mol Med.  24, 513-21.

 

Vo, T. P., Madlener S., Bago-Horvath Z., Herbacek I., Stark N., Gridling M., Probst P., Giessrigl B., Bauer S., Vonach C., Saiko P., Grusch M., Szekeres T., Fritzer-Szekeres M., Jager W., Krupitza G., Soleiman A. (2009). Pro- and anti-carcinogenic mechanisms of piceatannol are activated dose-dependently in MCF-7 breast cancer cells. Carcinogenesis.

 

 

 

davor (ausgewählte)

 

Allerstorfer, S., Sonvilla G., Fischer H., Spiegl-Kreinecker S., Gauglhofer C., Setinek U., Czech T., Marosi C., Buchroithner J., Pichler J., Silye R., Mohr T., Holzmann K., Grasl-Kraupp B., Marian B., Grusch M., Fischer J., Micksche M., Berger W. (2008). <//span>FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities. Oncogene.  27, 4180-90.

 

Deli, A., Kreidl E., Santifaller S., Trotter B., Seir K., Berger W., Schulte-Hermann R., Rodgarkia-Dara C., Grusch M. (2008). Activins and activin antagonists in hepatocellular carcinoma. World J Gastroenterol.  14, 1699-709.

 

Grusch, M., Rodgarkia-Dara C., Bursch W., Schulte-Hermann R. (2008) Activins and the liver. In Jakowlew, S. (ed.), Transforming Growth Factor-Beta in Cancer Therapy, Volume I. Humana press, Totowa, NJ, pp. 483-508.

 

Lackner, A., Genta K., Koppensteiner H., Herbacek I., Holzmann K., Spiegl-Kreinecker S., Berger W., Grusch M. (2008). A bicistronic baculovirus vector for transient and stable protein expression in mammalian cells. Anal Biochem.  380, 146-8.

 

Sonvilla, G., Allerstorfer S., Stattner S., Karner J., Klimpfinger M., Fischer H., Grasl-Kraupp B., Holzmann K., Berger W., Wrba F., Marian B., Grusch M. (2008). <//span>FGF18 in colorectal tumour cells: autocrine and paracrine effects. Carcinogenesis.  29, 15-24.

 

Drucker, C., Parzefall W., Teufelhofer O., Grusch M., Ellinger A., Schulte-Hermann R., Grasl-Kraupp B. (2006). Non-parenchymal liver cells support the growth advantage in the first stages of hepatocarcinogenesis. Carcinogenesis. 27, 152-161.

 

Grusch, M., Drucker C., Peter-Vorosmarty B., Erlach N., Lackner A., Losert A., Macheiner D., Schneider W. J., Hermann M., Groome N. P., Parzefall W., Berger W., Grasl-Kraupp B., Schulte-Hermann R. (2006). <//span>Deregulation of the activin/follistatin system in hepatocarcinogenesis. J Hepatol.  45, 673-80.

 

Losert, A., Mauritz I., Erlach N., Herbacek I., Schulte-Hermann R., Holzmann K., Grusch M. (2006). Monitoring viral decontamination procedures with green fluorescent protein-expressing adenovirus. Anal Biochem. 355, 310-312.

 

Rodgarkia-Dara, C., Vejda S., Erlach N., Losert A., Bursch W., Berger W., Schulte-Hermann R., Grusch M. (2006). The activin axis in liver biology and disease. Mutat Res. 613, 123-37.

 

Leisser, C., Rosenberger G., Maier S., Fuhrmann G., Grusch M., Strasser S., Huettenbrenner S., Fassl S., Polgar D., Krieger S., Cerni C., Hofer-Warbinek R., DeMartin R., Krupitza G. (2004). Subcellular localisation of Cdc25A determines cell fate. Cell Death Differ. 11, 80-9.

 

Fassl, S., Leisser C., Huettenbrenner S., Maier S., Rosenberger G., Strasser S., Grusch M., Fuhrmann G., Leuhuber K., Polgar D., Stani J., Tichy B., Nowotny C., Krupitza G. (2003). Transferrin ensures survival of ovarian carcinoma cells when apoptosis is induced by TNFalpha, FasL, TRAIL, or Myc. Oncogene.  22, 8343-55.

 

Vejda, S., Erlach N., Peter B., Drucker C., Rossmanith W., Pohl J., Schulte-Hermann R., Grusch M. (2003). Expression of activins C and E induces apoptosis in human and rat hepatoma cells. Carcinogenesis.  24, 1801-9.

 

Grusch, M., Polgar D., Gfatter S., Leuhuber K., Huettenbrenner S., Leisser C., Fuhrmann G., Kassie F., Steinkellner H., Smid K., Peters G. J., Jayaram H. N., Klepal W., Szekeres T., Knasmuller S., Krupitza G. (2002). Maintenance of ATP favours apoptosis over necrosis triggered by benzamide riboside. Cell Death Differ.  9, 169-78.

 

Grusch, M., Fritzer-Szekeres M., Fuhrmann G., Rosenberger G., Luxbacher C., Elford H. L., Smid K., Peters G. J., Szekeres T., Krupitza G. (2001). Activation of caspases and induction of apoptosis by novel ribonucleotide reductase inhibitors amidox and didox. Exp Hematol.  29, 623-32.

 

Mullauer, L., Mosberger I., Grusch M., Rudas M., Chott A. (2000). Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer. J Pathol.  190, 20-30.

 

Grusch, M., Rosenberger G., Fuhrmann G., Braun K., Titscher B., Szekeres T., Fritzer-Skekeres M., Oberhuber G., Krohn K., Hengstschlaeger M., Krupitza G., Jayaram H. N. (1999). Benzamide riboside induces apoptosis independent of Cdc25A expression in human ovarian carcinoma N.1 cells. Cell Death Differ.  6, 736-44.

 

Jayaram, H. N., Cooney D. A., Grusch M., Krupitza G. (1999). Consequences of IMP dehydrogenase inhibition, and its relationship to cancer and apoptosis. Curr Med Chem.  6, 561-74.

 

Krupitza, G., Grusch M., Braun K., Fuhrmann G., Steinbrugger R., Hulla W., Simonitsch I., Chott A., Hengstschlager M. (1998). TNFalpha-mediated cell death is independent of cdc25A. Cell Death Differ.  5, 758-64.

 

Grusch, M., Barth F. G., Egutchi E. (1997). Fine structural correlates of sensitivity in the eyes of the ctenid spider, Cupiennius salei Keys. Tissue and Cell. 29, 421-30.

 

Webseiten


SciTopics:

Grusch M, Kreidl E. Activin and follistatin in liver biology and hepatocellular carcinoma


Gene Atlas:

Grusch M . FSTL3 (follistatin-like 3 (secreted glycoprotein)). Atlas Genet Cytogenet Oncol Haematol. January 2009.

Grusch M . FST (follistatin). Atlas Genet Cytogenet Oncol Haematol. March 2010.